Series B
$25m
Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic
Cancer immunotherapy biotech Pathios Therapeutics has completed the initial tranche of a Series B round, bringing in Bristol Myers Squibb as a new strategic backer alongside prior backers Canaan and Brandon Capital.